Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease

Tags: ASCO GI Conference CoverageColorectal

Published: 16 January 2021

Recent Videos: ASCO GI Conference Coverage

video

Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, tells us about bemarituzumab (an anti-FGFR2b antibody) and elaborates on ...

video

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses zanidatamab (a bi-specific anti-HER2 antibody) and the updated data ...

video

Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer

Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, offers opinion on the FDA approval of trastuzumab deruxtecan for ...

video

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer ...

video

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer ...

video

Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

video

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC

Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, ...

Related Videos

video-image

Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021

video-image

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

video-image

Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer

video-image

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

video-image

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

video-image

Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021

video-image

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

video-image

Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing

video-image

Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

video-image

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC

video-image

Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021

video-image

Namrata Vijayvergia, MD, considers updated data from the CheckMate 040 trial in advanced HCC

video-image

Namrata Vijayvergia, MD, offers opinion on the use of FGFR inhibitors in the treatment of CCA

video-image

Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

video-image

Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial

video-image

Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

video-image

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

video-image

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

video-image

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

video-image

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

video-image

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

video-image

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

video-image

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

video-image

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

video-image

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

video-image

Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer

video-image

Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

video-image

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

video-image

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients

video-image

Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise

video-image

Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment

video-image

Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era

video-image

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

video-image

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O

video-image

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

video-image

Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer

video-image

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

video-image

Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients

video-image

Howard Hochster, MD, shares his opinion of the "watch and wait" strategy as presented in the OPRA study

video-image

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers

video-image

Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study

video-image

Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC

video-image

Alan Venook, MD, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers

video-image

Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer

video-image

Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study

video-image

Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC

video-image

Alan Venook, MD, discusses uniqueness of MSI-High/mismatch repair deficient CRC patients

video-image

Tanios Bekaii-Saab, MD, FACP discusses how strategies for the treatment of colorectal cancer patients has changed at the Mayo Clinic as a result of COVID-19

video-image

Tanios Bekaii-Saab, MD, FACP, describes deintensification strategies in the management of advanced colorectal cancer patients brought to the forefront by COVID-19